within Pharmacolibrary.Drugs.ATC.N;

model N05AC02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 12.0,            
    Vdp             = 0.011,
    k12             = 6.4,
    k21             = 6.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Thioridazine is a first-generation (typical) antipsychotic drug of the phenothiazine class. It was primarily used to manage symptoms of schizophrenia and psychosis. Due to its risk of cardiac arrhythmias (QT prolongation) and other side effects, thioridazine has been withdrawn or restricted in many countries and is no longer widely used or approved.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>DeVane, CL, &amp; Nemeroff, CB (2001). Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. <i>Clinical pharmacokinetics</i> 40(7) 509–522. DOI:<a href=\"https://doi.org/10.2165/00003088-200140070-00003\">10.2165/00003088-200140070-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11510628/\">https://pubmed.ncbi.nlm.nih.gov/11510628</a></p></li><li><p>Potkin, SG, et al., &amp; Arvanitis, LA (2002). The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. <i>Journal of clinical psychopharmacology</i> 22(2) 121–130. DOI:<a href=\"https://doi.org/10.1097/00004714-200204000-00004\">10.1097/00004714-200204000-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11910256/\">https://pubmed.ncbi.nlm.nih.gov/11910256</a></p></li><li><p>Padhi, D, &amp; Harris, R (2009). Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. <i>Clinical pharmacokinetics</i> 48(5) 303–311. DOI:<a href=\"https://doi.org/10.2165/00003088-200948050-00002\">10.2165/00003088-200948050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19566113/\">https://pubmed.ncbi.nlm.nih.gov/19566113</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AC02;
